Related references
Note: Only part of the references are listed.Cancer Statistics, 2012
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100
Juliet Richards et al.
CANCER RESEARCH (2012)
Abiraterone in Prostate Cancer: A New Angle to an Old Problem
Mark N. Stein et al.
CLINICAL CANCER RESEARCH (2012)
Targeting of pancreatic and prostate cancer stem cell characteristics by Crambe crambe marine sponge extract
Sabine Ottinger et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Under-Representation of Older Adults in Cancer Registration Trials: Known Problem, Little Progress
Kevin S. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Prostate cancer stem cells: Are they androgen-responsive?
Emma E. Oldridge et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2012)
Troglitazone suppresses c-Myc levels in human prostate cancer cells via a PPARγ-independent mechanism
Tunde O. Akinyeke et al.
CANCER BIOLOGY & THERAPY (2011)
Interleukin-1α Mediates the Antiproliferative Effects of 1,25-Dihydroxyvitamin D3 in Prostate Progenitor/Stem Cells
Sophia L. Maund et al.
CANCER RESEARCH (2011)
Reversing Breast Cancer Stem Cell into Breast Somatic Stem Cell
L. Wijaya et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2011)
Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)
C. Parker et al.
EUROPEAN JOURNAL OF CANCER (2011)
New Therapies for Castration-Resistant Prostate Cancer: Efficacy and Safety
Himisha Beltran et al.
EUROPEAN UROLOGY (2011)
Gamma-tocotrienol as an effective agent in targeting prostate cancer stem cell-like population
Sze Ue Luk et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Vitamin E and the Risk of Prostate Cancer The Selenium and Vitamin E Cancer Prevention Trial (SELECT)
Eric A. Klein et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Cancer stem cells: problems for therapy?
Malcolm R. Alison et al.
JOURNAL OF PATHOLOGY (2011)
Vitamin D metabolism and action in the prostate: Implications for health and disease
Srilatha Swami et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2011)
Sulforaphane Increases Drug-mediated Cytotoxicity Toward Cancer Stem-like Cells of Pancreas and Prostate
Georgios Kallifatidis et al.
MOLECULAR THERAPY (2011)
The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44
Can Liu et al.
NATURE MEDICINE (2011)
The cancer stem cell: premises, promises and challenges
Hans Clevers
NATURE MEDICINE (2011)
The changing therapeutic landscape of castration-resistant prostate cancer
Timothy A. Yap et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Galiellalactone Inhibits Stem Cell-Like ALDH-Positive Prostate Cancer Cells
Rebecka Hellsten et al.
PLOS ONE (2011)
Prostate Cancer Stem Cells: Do They Have a Basal or Luminal Phenotype?
Norman J. Maitland et al.
Hormones & Cancer (2011)
Combination Therapy Targeting Both Tumor-Initiating and Differentiated Cell Populations in Prostate Carcinoma
Anna Dubrovska et al.
CLINICAL CANCER RESEARCH (2010)
The therapeutic promise of the cancer stem cell concept
Natasha Y. Frank et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Yang-Min Ning et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prolonged Drug Selection of Breast Cancer Cells and Enrichment of Cancer Stem Cell Characteristics
Anna Maria Calcagno et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study
Howard I. Scher et al.
LANCET (2010)
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann Sebastian de Bono et al.
LANCET (2010)
Primitive origins of prostate cancer: In vivo evidence for prostate-regenerating cells and prostate cancer-initiating cells
Andrew S. Goldstein et al.
MOLECULAR ONCOLOGY (2010)
Effect of Dutasteride on the Risk of Prostate Cancer.
Gerald L. Andriole et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Basal epithelial stem cells are efficient targets for prostate cancer initiation
Devon A. Lawson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Embryonic stem cell markers expression in cancers
Matthieu Schoenhals et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Miguel A. Sanz et al.
BLOOD (2009)
Differentiation therapy of leukemia: 3 decades of development
Daniel Nowak et al.
BLOOD (2009)
Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
Piyush B. Gupta et al.
CELL (2009)
DLL4 Blockade Inhibits Tumor Growth and Reduces Tumor-Initiating Cell Frequency
Timothy Hoey et al.
CELL STEM CELL (2009)
Characterizing the Clinical Relevance of an Embryonic Stem Cell Phenotype in Lung Adenocarcinoma
Marvaretta Stevenson et al.
CLINICAL CANCER RESEARCH (2009)
Combined Targeted Treatment to Eliminate Tumorigenic Cancer Stem Cells in Human Pancreatic Cancer
Maria-Theresa Mueller et al.
GASTROENTEROLOGY (2009)
Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
Gerhardt Attard et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Tumour-initiating cells: challenges and opportunities for anticancer drug discovery
Bin-Bing S. Zhou et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations
Anna Dubrovska et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Targeting of Prostate Cancer Cells by a Cytotoxic Lentiviral Vector Containing a Prostate Stem Cell Antigen (PSCA) Promoter
Frank A. Petrigliano et al.
PROSTATE (2009)
CD44+CD24- prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis
E. M. Hurt et al.
BRITISH JOURNAL OF CANCER (2008)
Perifosine induces differentiation and cell death in prostate cancer cells
Daniel Floryk et al.
CANCER LETTERS (2008)
An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors
Ittai Ben-Porath et al.
NATURE GENETICS (2008)
Colorectal Cancer Stem Cells Are Enriched in Xenogeneic Tumors Following Chemotherapy
Scott J. Dylla et al.
PLOS ONE (2008)
Drug-Selected Human Lung Cancer Stem Cells: Cytokine Network, Tumorigenic and Metastatic Properties
Vera Levina et al.
PLOS ONE (2008)
Expression profiling of CD133+ and CD133- epithelial cells from human prostate
Christopher J. Shepherd et al.
PROSTATE (2008)
Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions
Richard Birnie et al.
GENOME BIOLOGY (2008)
CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway
S. Ma et al.
ONCOGENE (2008)
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions
Jane E. Visvader et al.
NATURE REVIEWS CANCER (2008)
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer
Michael A. Carducci et al.
CANCER (2007)
Hierarchical organization of prostate cancer cells in xenograft tumors:: The CD44+α2β1+ cell population is enriched in tumor-initiating cells
Lubna Patrawala et al.
CANCER RESEARCH (2007)
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer:: a randomised, multicentre, placebo-controlled phase II study
Sten Nilsson et al.
LANCET ONCOLOGY (2007)
A human colon cancer cell capable of initiating tumour growth in immunodeficient mice
Catherine A. O'Brien et al.
NATURE (2007)
Diagnosis of adenocarcinoma in prostate needle biopsy tissue
P. A. Humphrey
JOURNAL OF CLINICAL PATHOLOGY (2007)
Mycophenolic acid-induced replication arrest, differentiation markers and cell death of androgen-independent prostate cancer cells DU145
D Floryk et al.
CANCER LETTERS (2006)
Natural and synthetic retinoids in prostate cancer
D. Pasquali et al.
CURRENT PHARMACEUTICAL DESIGN (2006)
Prospective identification of tumorigenic prostate cancer stem cells
AT Collins et al.
CANCER RESEARCH (2005)
Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPAR-γ
CW Shiau et al.
CANCER RESEARCH (2005)
Pilot study: Potential role of vitamin D (cholecalciferol) in patients with PSA relapse after definitive therapy
TCS Woo et al.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL (2005)
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate
CMR Lima et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
The impact of low-dose busulfan on clonal dynamics in nonhuman primates
K Kuramoto et al.
BLOOD (2004)
CD133, a novel marker for human prostatic epithelial stem cells
GD Richardson et al.
JOURNAL OF CELL SCIENCE (2004)
Stem cell origin of cancer and differentiation therapy
S Sell
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2004)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Differentiating agents and the treatment of prostate cancer:: Vitamin D3 and peroxisome proliferator-activated receptor gamma ligands
SB Leibowitz et al.
SEMINARS IN ONCOLOGY (2003)
The influence of finasteride on the development of prostate cancer
IM Thompson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma
JA Child et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Prospective identification of tumorigenic breast cancer cells
M Al-Hajj et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
F Saad et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
Modulation of cell proliferation and cell cycle regulators by vitamin E in human prostate carcinoma cell lines
V Venkateswaran et al.
JOURNAL OF UROLOGY (2002)
Expression of basal cell keratins in human prostate cancer metastases and cell lines
GJLH van Leenders et al.
JOURNAL OF PATHOLOGY (2001)
Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer
E Mueller et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
